Clinical Trial

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330）versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.
Trial Details
NCT Number NCT07177716
Lead Sponsor L & L Bio Co., Ltd., Ningbo, China
Conditions Cervical Cancer
Enrollment 120 participants
Start Date 2025-10
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-17